leukemia after failure of first-line imatinib: a randomized phase 2 trial Dasatinib or high-dose imatinib for chronic-phase chronic myeloid
暂无分享,去创建一个
J. Radich | P. Rousselot | T. Robak | A. Skotnicki | N. Shah | T. Masszi | N. Hamerschlak | T. Hughes | R. Pasquini | J. Hołowiecki | A. Zaritsky | A. Golenkov | Khoroshko Nd | A. Kantarjian | T. Hughes
[1] M. Litzow. Imatinib resistance: obstacles and opportunities. , 2009, Archives of pathology & laboratory medicine.
[2] R. Larson,et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. , 2007, Blood.
[3] M. Baccarani,et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. , 2007, Blood.
[4] M. Baccarani,et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. , 2007, Blood.
[5] Francisco Cervantes,et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.
[6] H. Kantarjian,et al. Dynamics of molecular response to dasatinib (BMS-354825) in patients (pts) with chronic myelogenous leukemia (CML) resistant or intolerant to imatinib. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] R. Larson,et al. Dasatanib (D) in patients (pts) with chronic myelogenous leukemia (CML) in lymphoid blast crisis (LB-CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are imatinib (IM)-resistant (IM-R) or intolerant (IM-I): The CA180015 'START-L' study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Susan O'Brien,et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.
[9] M. Wittekind,et al. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. , 2006, Cancer research.
[10] Moshe Talpaz,et al. Dasatinib (BMS-354825) Tyrosine Kinase Inhibitor Suppresses Invasion and Induces Cell Cycle Arrest and Apoptosis of Head and Neck Squamous Cell Carcinoma and Non–Small Cell Lung Cancer Cells , 2005, Clinical Cancer Research.
[11] B. Druker,et al. Combined Abl Inhibitor Therapy for Minimizing Drug Resistance in Chronic Myeloid Leukemia: Src/Abl Inhibitors Are Compatible with Imatinib , 2005, Clinical Cancer Research.
[12] C. Sawyers,et al. A phase I study of BMS-354825 in patients with imatinib-resistant and intolerant chronic phase chronic myeloid leukemia (CML): Results from CA180002 , 2005 .
[13] Susan O'Brien,et al. Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate , 2005, Clinical Cancer Research.
[14] Ping Chen,et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.
[15] C. Sawyers,et al. Four Years of Follow-Up of 1027 Patients with Late Chronic Phase (L-CP), Accelerated Phase (AP), or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Treated with Imatinib in Three Large Phase II Trials. , 2004 .
[16] J. Tokarski,et al. The Crystal Structure of Abl Kinase with BMS-354825, a Dual SRC/ABL Kinase Inhibitor. , 2004 .
[17] Ping Chen,et al. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.
[18] F. Guilhot. Indications for imatinib mesylate therapy and clinical management. , 2004, The oncologist.
[19] A. Hochhaus,et al. Clinical resistance to imatinib: mechanisms and implications. , 2004, Hematology/oncology clinics of North America.
[20] H. Kantarjian,et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. , 2004, Blood.
[21] D. Marin,et al. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. , 2003, Blood.
[22] J. Zonder,et al. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[23] R. Clark,et al. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia , 2003, British journal of haematology.
[24] H. Kantarjian,et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. , 2003, Blood.
[25] N. Shah. Loss of response to imatinib: mechanisms and management. , 2005, Hematology. American Society of Hematology. Education Program.